# Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Study · id `cardio:ct-nct02334488` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02334488](<https://clinicaltrials.gov/study/NCT02334488>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02334488

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.

## Technical summary

Registry record NCT02334488. Randomized; no masking; primary purpose treatment. Start 2014-12-11 (actual); primary completion 2019-05-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 329 participants (enrolled count; ClinicalTrials.gov record NCT02334488, source copy `cardio:ctgov-nct02334488-2021-01-29`, retrieved 2026-10-26)
- Started: 2014-12-11 (actual) (ClinicalTrials.gov record NCT02334488, source copy `cardio:ctgov-nct02334488-2021-01-29`, retrieved 2026-10-26)
- Primary completion: 2019-05-31 (actual) (ClinicalTrials.gov record NCT02334488, source copy `cardio:ctgov-nct02334488-2021-01-29`, retrieved 2026-10-26)
- Completion: 2020-07-03 (actual) (ClinicalTrials.gov record NCT02334488, source copy `cardio:ctgov-nct02334488-2021-01-29`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT02334488, source copy `cardio:ctgov-nct02334488-2021-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02334488-2021-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function
- Condition: Chronic Kidney Disease
- Intervention (Drug): Everolimus
- Intervention (Drug): Tacrolimus
- Intervention (Drug): Mycophenolate sodium
- Lead sponsor: Poitiers University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Poitiers University Hospital (`cardio:org-poitiers-university-hospital`)

## Provenance

Content hash: 6f372183ef55be45c12497e6124df0fb520c00e0a2bac06c7af296bfba3d6533
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
